Rubius Therapeutics

Rubius Therapeutics appoints Chief Medical Officer Chris Carpenter

Wednesday, September 27, 2017

Rubius Therapeutics, a “Fierce 15” company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, announced the appointment of Chris Carpenter, M.D., Ph.D., as chief medical officer. Dr. Carpenter will oversee Rubius’ clinical and regulatory strategy as the company prepares to enter human clinical trials in 2018. In addition, Rubius announced the appointments of Joanne Protano as vice president of finance; Mark Boshar as vice president of legal affairs; and Theo Proukou as vice president of human resources.

[Read More]